Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:DYAX

Dyax (DYAX) Stock Price, News & Analysis

→ Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad)
Free DYAX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$38.41
▼
$38.41
50-Day Range
N/A
52-Week Range
$14.06
▼
$38.56
Volume
N/A
Average Volume
5.25 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
DYAX stock logo

About Dyax Stock (NASDAQ:DYAX)

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

DYAX Stock News Headlines

May 14, 2024 | finance.yahoo.com
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
September 7, 2023 | finanznachrichten.de
Anokion SA: Anokion Strengthens its Senior Leadership with Promotions and New Appointment
September 7, 2023 | finance.yahoo.com
Anokion Strengthens its Senior Leadership with Promotions and New Appointment
July 17, 2023 | msn.com
Most immigrants in West Virginia are from these countries
July 17, 2023 | msn.com
Is David Corenswet A Good Fit For Superman? Here's How /Film Readers Feel
July 17, 2023 | msn.com
Most immigrants in Virginia are from these countries
July 11, 2023 | benzinga.com
Cytophage Technologies Inc. Board of Directors Welcomes New Member and Board Advisor
July 7, 2023 | msn.com
Janhvi and Khushi Kapoor shower love Boney Kapoor as he cooks breakfast for Anshula
May 16, 2023 | marketwatch.com
Next-Generation Antibody Therapeutics Market Price & News with Share Forecast
May 12, 2023 | marketwatch.com
S-1: NutriBand Inc.
May 10, 2023 | finance.yahoo.com
Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel
March 24, 2023 | insidermonkey.com
Astria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Call Transcript
March 14, 2023 | marketwatch.com
Next-Generation Antibody Therapeutics Market Analysis: Understanding The Current State and Future Trends 2023-2028
March 13, 2023 | marketwatch.com
Next-Generation Antibody Therapeutics Market Outlook and Forecast to 2029 with Top Countries Data
March 8, 2023 | marketwatch.com
Next Generation Antibody Therapeutics Market Size, Latest Trends, Share, Top Players, Revenue and Forecast 2028
March 4, 2023 | msn.com
HOOPS RECAP: In UT’s first full game without Zakai Ziegler, Tennessee fails to hit a shot during the final six minutes of the game, loses to Auburn 79-70
February 26, 2023 | marketwatch.com
Next-Generation Antibody Therapeutics Market Size, Analysis with Key Players having Regional Statistics and Application Forecast to 2028
January 11, 2023 | msn.com
Peter Hotez on new COVID XBB1.5 variant: 'People are saying this will be mild. It's not mild'
January 2, 2023 | thestreet.com
Drug Giant Shire Snaps Up Biotech Dyax for $5.9 Billion
December 24, 2022 | seekingalpha.com
Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm
December 13, 2022 | msn.com
Noisy toys and hearing damage with Ascent Audiology & Hearing
November 28, 2022 | msn.com
Commentary: There are those who get out of the water when there’s a shark, and those who get in
November 18, 2022 | msn.com
Instagrammer shares how their tiny ‘kitchen composter’ makes food waste disappear: ‘Everyone needs one’
November 17, 2022 | msn.com
No more deaths recorded in Bristol
November 2, 2022 | msn.com
Martin Lewis says thousands being ripped off when it comes to savings rates
See More Headlines

Company Calendar

Last Earnings
10/28/2015
Today
5/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DYAX
CUSIP
26746E10
CIK
907562
Web
www.dyax.com
Phone
+1-617-2505769
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

DYAX Stock Analysis - Frequently Asked Questions

How were Dyax's earnings last quarter?

Dyax Corp (NASDAQ:DYAX) posted its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.96 million. Dyax's revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.01) EPS.

What other stocks do shareholders of Dyax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD), Novavax (NVAX), Prudential (PRU), Standard Chartered (STAN), Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA).

This page (NASDAQ:DYAX) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
The ONE AI Stock to own now. (It’s not Nvidia.)
Weiss Ratings
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
Warren Buffett's "mystery stock"
Stansberry Research
This Could be Your “Big Money” AI Moment
InvestorPlace